Nurix Therapeutics, Inc. (NRIX) Stock Score, Valuation & Financial Research
Nurix Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 22/100.
Quick answer for NRIX
Nurix Therapeutics, Inc. currently has a Wall Street Score of 22/100. The stored market price is $25.52. Its financial score is 35/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Nurix Therapeutics, Inc. does
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and ot
NRIX financial snapshot
- Wall Street Score:
- 22/100
- Current price:
- $25.52
- Market capitalization:
- $2.65B
- Revenue:
- $36.8M
- Net income:
- $-341.4M
- Free cash flow:
- $-263.5M
- Cash:
- $67.7M
- Total debt:
- $58.1M
- EPS:
- -3.05
- Financial score:
- 35/100
- Valuation score:
- 0/100
- Revenue score:
- 4/100
What stands out
- Reported year-over-year revenue growth is -0.6%.
- Free cash flow is $-263.5M, showing cash burn in the current stored period.
- The balance sheet shows $67.7M of cash versus $58.1M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 35/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research NRIX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.